Cargando…

Immune-related adverse events: A bibliometric analysis

BACKGROUND: Despite providing clinical benefit, immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) in a number of patients. This study explored the development pattern in irAEs research from a bibliometric perspective. METHODS: We obtained articles and reviews relate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Shi-Tao, Liu, Yao-Ge, Zhang, Lei, Sang, Xin-Ting, Xu, Yi-Yao, Lu, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797501/ https://www.ncbi.nlm.nih.gov/pubmed/36591239 http://dx.doi.org/10.3389/fimmu.2022.1096806

Ejemplares similares

Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
por: Zeng, Li, et al.
Publicado: (2023)

Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study
por: Liu, Yao-Ge, et al.
Publicado: (2023)

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
por: Zhou, Lin, et al.
Publicado: (2021)

Immunogenomic correlates of immune-related adverse events for anti–programmed cell death 1 therapy
por: Zhang, Lei, et al.
Publicado: (2022)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Trends in immune-related adverse events for colorectal cancer: A bibliometric analysis
por: Cui, Jin, et al.
Publicado: (2022)

Association between germ-line HLA and immune-related adverse events
por: Jiang, Ning, et al.
Publicado: (2022)

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
por: Poto, Remo, et al.
Publicado: (2022)

Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events
por: Liu, Xinyu, et al.
Publicado: (2023)

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
por: Wang, Min, et al.
Publicado: (2021)

Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction
por: Cao, Ting, et al.
Publicado: (2023)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
por: Glehr, Gunther, et al.
Publicado: (2022)

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
por: Hamada, Kazuyuki, et al.
Publicado: (2023)

Bibliometric Analysis of γδ T Cells as Immune Regulators in Cancer Prognosis
por: Liu, Bing, et al.
Publicado: (2022)

Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Xu, Shuo, et al.
Publicado: (2021)

Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events
por: Müller-Jensen, Leonie, et al.
Publicado: (2023)

Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
por: Les, Iñigo, et al.
Publicado: (2021)

Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events
por: Müller, Benjamin, et al.
Publicado: (2023)

Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis
por: Zhao, Qing, et al.
Publicado: (2021)

Co-Inhibitory Molecules – Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events
por: Greisen, Stinne R., et al.
Publicado: (2022)

Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
por: Zhang, Wei, et al.
Publicado: (2023)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy
por: Hu, Wei-Ting, et al.
Publicado: (2023)

Autoimmune pancreatitis: A bibliometric analysis from 2002 to 2022
por: Zhang, Xian-Da, et al.
Publicado: (2023)

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers
por: Wang, Yanni, et al.
Publicado: (2022)

Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations
por: Williams, Kristian C., et al.
Publicado: (2023)

Bibliometric analysis of global research trends on pyroptosis in lung disease
por: Mo, Wei, et al.
Publicado: (2022)

Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor
por: Bai, Xin, et al.
Publicado: (2021)

Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis
por: Hao, Wenjing, et al.
Publicado: (2023)

Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study
por: Luangnara, Athitaya, et al.
Publicado: (2022)

Knowledge mapping of image-guided tumor ablation and immunity: A bibliometric analysis
por: Shen, Hui, et al.
Publicado: (2023)

A Bibliometric Analysis of the Innate Immune DNA Sensing cGAS-STING Pathway from 2013 to 2021
por: Shi, Xuan, et al.
Publicado: (2022)

Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
por: Anderson, Ronald, et al.
Publicado: (2019)

Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer
por: Qin, Wenru, et al.
Publicado: (2022)

Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells
por: Gazzano, Marianne, et al.
Publicado: (2022)

A bibliometric analysis of T cell and atherosclerosis
por: Wei, Namin, et al.
Publicado: (2022)

Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
por: Xie, Xiaohong, et al.
Publicado: (2022)

Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhou, Juyue, et al.
Publicado: (2023)

Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy
por: Wang, Haowei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kf4kjs4a6fbjn12bvsb07pcdd7